How Is The Market Feeling About Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals's (NYSE:ALNY) short percent of float has fallen 9.57% since its last report. The company recently reported that it has 2.80 million shares sold short, which is 2.55% of all reg

BenzingaApr 19 14:30 ET

Press Release: Alnylam to Webcast Conference Call Discussing First Quarter 2024 Financial Results

Alnylam to Webcast Conference Call Discussing First Quarter 2024 Financial Results CAMBRIDGE, Mass.--(BUSINESS WIRE)--April 18, 2024-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi

Dow JonesApr 18 08:06 ET

Alnylam to Webcast Conference Call Discussing First Quarter 2024 Financial Results

Alnylam to Webcast Conference Call Discussing First Quarter 2024 Financial ResultsApr 18, 2024CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 18, 2024-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the lead

Alnylam Pharmaceuticals, Inc.Apr 18 00:00 ET

Wolfe Upgrades Ionis to Outperform, Cites Upcoming Catalysts

Seeking AlphaApr 10 12:03 ET

10 Health Care Stocks With Whale Alerts In Today's Session

This whale alert can help traders discover the next big trading opportunities.Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scan

BenzingaApr 9 13:35 ET

Analysts Express Confidence in Alnylam's Hypertension Drug Despite Mixed Trial Data

On Sunday, Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) presented results from the KARDIA-2 Phase 2 study, which evaluated the efficacy and safety of a single subcutaneous dose of zilebesiran when added

BenzingaApr 8 14:37 ET